Bay City Capital GF Xinde is a cross-border life sciences venture capital fund with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. To learn more, visit www.baycitycapital.com or www.gf.com.cn.
Earlybird is a venture capital investor focused on European technology innovators. Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support, as well as access to an international network and capital markets. www.earlybird.com
Novartis Venture Fund is a financially driven corporate life science fund whose purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life sciences companies at various stages of their development. To learn more, visit www.nvfund.com.
Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts and is the investment adviser for four closed-end funds, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. The Funds predominately invest in the securities of public and private healthcare companies. www.teklacap.com
Brunnur Ventures GP is the general partner of Brunnur VC Fund, an ISK 4bn (approx. USD 38m as of January 2018) venture capital fund established in 2015. The Fund invests in Icelandic start-up companies with innovative, scalable business models, extraordinary entrepreneurial talent and a strong competitive edge generated by patentable technology or exclusive, proprietary know-how. To learn more, visit www.brunnurventures.com
Hyfinity Investments is devoted to advancing global innovation targeting high unmet needs and bringing in the rich clinical resources in China. Hyfinity Investments is led by senior partners from top-tier investment institutions in China, with years of experience in healthcare investment, local operation, and overseas licensing. Its mission is to foster industry leaders through converging resources globally. www.hyfinityfund.com
Pivotal bioVenture Partners is a $300MM venture capital fund established in 2017. Based in San Francisco, California, the fund invests in US and European companies with a primary focus on innovative therapeutic solutions to major unmet medical needs. To learn more, visit www.pivotalbiovp.com.
VI Partners is the longest-established Swiss VC firm. Since more than 20 years, VI Partners has been supporting innovative Healthcare and Technology companies, investing over CHF 250m in 55 ventures. VI Partners initially has been advising Venture Incubator fund, an investment vehicle founded by ten blue-chip Swiss corporations, and more recently established VI Partners Swiss Innovation Fund. www.vipartners.ch
BVCF Management, Ltd. (“BVCF”) is a healthcare investment company that launches and manages funds which invest in global growth stage healthcare companies with a China focus. BVCF actively assist business owners and entrepreneurs to build their companies into world-class businesses. To date, BVCF has raised five funds; it is headquartered in Shanghai, China with offices in Beijing and Hong Kong SAR. www.bvcf.com
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Nan Fung Group, founded in 1954, is a conglomerate based in Hong Kong with global interests in real estate development and investment, life sciences and financial investments. Learn more at www.nanfung.com.
Silfurberg is an international, venture capital firm located in Reykjavík Iceland. Silfurberg specializes in investments in early-stage health care, biotech and other life science opportunities. www.silfurberg.is
Wille AG is a Multi Family Office based in Switzerland. Wille AG is an active private equity investor in Life Science and Software venture companies as well as in Buy-Out companies. Wille’s portfolio encompasses 35 companies across Europe, Israel and the US. www.willefinance.com
One of Oculis pre-clinical project has received funding from the Icelandic Technology Development Fund and the Eurostars-2 Joint Programme with co-funding from the European Union’s Horizon 2020 research and innovation programme.